Search | Clinical Trials Finder

Conditions: Contraception
Interventions: Norethindrone 1 mg / ethinyl estradiol 20 mcg; Drug
Lead sponsor: Warner Chilcott; Industry
Eligibility: 25 Years to 40 Years · Female only
Enrollment: 207 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 23
States / cities: Phoenix, Arizona • Tempe, Arizona • Carmichael, California + 18 more

Conditions: Stroke, Acute
Interventions: Desmoteplase, Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 193 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 28
States / cities: Birmingham, Alabama • Los Angeles, California • Delray Beach, Florida + 20 more

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: high-selenium Brassica juncea, capecitabine, irinotecan hydrochloride; Dietary Supplement · Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 2
States / cities: Duarte, California • Pasadena, California

Conditions: Diabetes Mellitus, Type II
Interventions: Insulin lispro, Insulin aspart, Recombinant human hyaluronidase PH20, Insulin glulisine, Insulin glargine; Drug
Lead sponsor: Halozyme Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 22
States / cities: Concord, California • Encino, California • Escondido, California + 18 more

Conditions: Ligament Injury
Interventions: Oral Contraceptive Pill, norethindrn a-e estradiol-iron; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 73 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Dermatitis, Atopic
Interventions: LY3471851, Placebo; Drug
Lead sponsor: Nektar Therapeutics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 20
States / cities: North Little Rock, Arkansas • Encinitas, California • Fremont, California + 17 more

Conditions: Respiratory Failure, Hypotension and Shock, Hypotension on Induction, Intubation Complication, Anesthesia Intubation Complication
Interventions: Norepinephrine, Lactated Ringers, Intravenous, normal saline, Plasma-lyte; Drug
Lead sponsor: Wright State University; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Dayton, Ohio

Conditions: Diabetic Nephropathies, Diabetic Kidney Disease
Interventions: Formoterol furmarate (20 μg); Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 75 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: EBV, Epstein-Barr Virus Infection, Infectious Mononucleosis
Interventions: EBV gp350-Ferritin Vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 29 Years
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hip Dysplasia
Interventions: Ropivacaine, Epinephrine, Ketorolac, NaCl (Saline); Combination Product
Lead sponsor: Michael C Willey; Other
Eligibility: 13 Years to 50 Years
Enrollment: 121 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Influenza
Interventions: Trivalent inactivated influenza vaccine, Trivalent Baculovirus-expressed Influenza HA vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Nicotine Dependence
Interventions: Nicotine saline infusion 0.00mcg/kg/s, Nicotine infusion 0.24mcg/kg/s, Nicotine infusion 0.096mcg/kg/s, Nicotine infusion 0.048 mcg/kg/s, Nicotine infusion 0.024mcg/kg/s; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 35 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Traumatic Brain Injury
Interventions: Recombinant human Growth Hormone, Placebo; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 50 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 3
States / cities: Bakersfield, California • Dallas, Texas

Conditions: Obesity, Insulin Resistance, Obesity in Diabetes, Nutritional and Metabolic Diseases, Hyperlipidemia, Hyperglycemia, Cardiovascular Diseases
Interventions: Placebo-Control, Low-Dose Vitamin K2 (menaquinone-7; 45-mcg/d), High-Dose Vitamin K2 (menaquinone-7; 90 mcg/d); Dietary Supplement
Lead sponsor: Augusta University; Other
Eligibility: 8 Years to 17 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases
Interventions: TransCon PTH, Placebo; Combination Product
Lead sponsor: Ascendis Pharma Bone Diseases A/S; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 9
States / cities: San Francisco, California • Chicago, Illinois • Rochester, Minnesota + 6 more

Conditions: Hospital Inpatient Trauma Injury, Pain Management
Interventions: Ketamine, Placebo; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years to 64 Years
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Tachycardia, Chronic Orthostatic Intolerance
Interventions: Acetazolamide, Atomoxetine, NO Drug, Clonidine, Entacapone, Entacapone & Propranolol, Atomoxetine & Propranolol, Indomethacin, Mecamylamine, Isosorbide Dinitrate, Melatonin, Midodrine, Modafinil, Octreotide, Placebo, Propranolol, Modafinil & Propranolol, Sertraline, IV Saline, Drinking Water, Breathing Device, memantine, Abdominal binder; Drug · Other · Dietary Supplement + 3 more
Lead sponsor: Satish R. Raj; Other
Eligibility: 18 Years to 70 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1997 – 2029
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Asthma
Interventions: RELVAR/BREO, Salbutamol, Smart phone app, HCP Dashboard, Sensors; Drug · Device
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 437 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 11
States / cities: Aventura, Florida • Miami, Florida • Flossmoor, Illinois + 8 more

Conditions: Memory Loss, Cognitive Changes, Postmenopausal Symptoms
Interventions: Estradiol oral capsule, transderman estrogen patch, trasdermal placebo patch, placebo oral capsule; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 45 Years to 80 Years · Female only
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Obstructive Sleep Apnea
Interventions: Budesonide, placebo; Drug
Lead sponsor: University of Louisville; Other
Eligibility: 6 Years to 12 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Vaginal Delivery
Interventions: saline, fentanyl/bupivacaine/epinephrine; Drug
Lead sponsor: Ochsner Health System; Other
Eligibility: 18 Years to 34 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: COVID-19, SARS-CoV-2
Interventions: CV0501 (3 μg), CV0501 (6 μg), CV0501 (12 μg), CV0501 (25 μg), CV0501 (50 μg), CV0501 (100 μg), CV0501 (200 μg); Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 185 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 11
States / cities: Sacramento, California • Hollywood, Florida • Melbourne, Florida + 8 more

Conditions: Cataract, Glaucoma, Ocular Hypertension
Interventions: Bimatoprost Implant System, SpyGlass IOL, Timolol Maleate Ophthalmic Solution, 0.5%, Commercial IOL; Drug · Device
Lead sponsor: SpyGlass Pharma, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Hepatitis C Virus
Interventions: Asunaprevir (ASV), Daclatasvir (DCV), Pegylated-interferon alfa 2a (PegIFN), Ribavirin (RBV); Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 748 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 18
States / cities: Montgomery, Alabama • La Jolla, California • Los Angeles, California + 14 more

Search by objective public record fields.

Study of Bleeding With Extended Administration of an Oral Contraceptive

Study of Desmoteplase (International Nonproprietary Name [INN]) in Acute Ischemic Stroke (DIAS-2)

High-Selenium Brassica Juncea, Irinotecan, and Capecitabine in Treating Patients With Advanced Cancer

Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes Mellitus

Do Oral Contraceptives Protect Against ACL Injuries in Female Athletes

A Study of LY3471851 in Participants With Eczema

Using Vasopressor Medication to Support Blood Pressure During Intubation Procedure

Formoterol in Diabetes

Safety and Immunogenicity of an Epstein-Barr Virus (EBV) gp350-Ferritin Nanoparticle Vaccine in Healthy Adults

Can PLIA Reduce Early Post-operative Pain After PAO Surgery?

High Dose Influenza in Immunosuppressed Subjects

Nicotine Delivery Rate and Its Abuse Potential: Impact of Menthol

Recombinant Human Growth Hormone During Rehabilitation From Traumatic Brain Injury.

Vitamin K to Slow Progression of Dyslipidemia and Diabetes Risk (Vita-K 'n' Kids Study II)

A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Daily in Adults With Hypoparathyroidism

Ketamine for Pain Control After Severe Traumatic Injury

Treatment of Orthostatic Intolerance

A Clinical Study to Evaluate the Effect of the Connected Inhaler System (CIS) on Adherence to Maintenance Therapy in Poorly Controlled Asthmatic Subjects

Aging and Estrogen on Cortical Function

Nasal Budesonide in Children With Rhinitis and/or Mild Obstructive Sleep Apnea Syndrome

The Effects of Combined Spinal Epidurals on Fever During Labor of First-Time Mothers

Safety and Immunogenicity Study of a Booster Dose of the Investigational CV0501 mRNA COVID-19 Vaccine in Adults at Least 18 Years Old

Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)

Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)